Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1998-6-10
pubmed:abstractText
The fluoroquinolones have secured an important place in the management of bacterial infection, they are well absorbed orally, are found in respiratory secretions in higher concentrations than in serum and are concentrated inside macrophages. The agents are well tolerated and have an excellent safety record in long-term therapy. No new antituberculosis agents have been developed since the introduction of rifampicin into clinical use, so fluoroquinolones have been investigated for potential efficacy in tuberculosis. In vitro studies have shown that they are active against Mycobacterium tuberculosis at achievable concentrations. Treatment studies in mice have demonstrated efficacy. Few clinical studies have been performed in humans, but ciprofloxacin has demonstrated significant early bactericidal activity. Regimens including a fluoroquinolone have been comparable to other standard regimens, although the outcome in human immunodeficiency virus (HIV) seropositive patients was significantly poorer. There is still insufficient clinical data to use fluoroquinolones in first-line treatment of tuberculosis, but they may find a role in the management of multidrug-resistant infections or in patients with adverse reactions to other agents.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1027-3719
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
265-71
pubmed:dateRevised
2006-6-12
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Fluoroquinolones: a new treatment for tuberculosis?
pubmed:affiliation
Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK. stepheng@rfhsm.ac.uk
pubmed:publicationType
Journal Article, Review